vVARDIS raises funding

vVARDIS is developing Curodont, a non-invasive, peptide-based treatment for caries. Funds managed by Apollo are taking a strategic minority stake, for an undisclosed amount, that values the company at more than USD 1 billion.

Announced on
Round
Undisclosed round
Amount
Amount not disclosed
Location
Zug
Sector
Health & medtech

Investors

  • Apollo

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic